在血液造血干细胞移植中用于供体选择的HLA和非HLA因子与移植后环胺GvHD预防治疗
1Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
Cells
|January 8, 2025
概括
移植后循环胺 (PTCy) 允许在干细胞移植中耐受良好的HLA不匹配. 供体选择优先考虑年轻的供体和特定的HLA匹配,患者抗体至关重要.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
背景情况:
- 人类白细胞抗原 (HLA) 不匹配传统上在干细胞移植中带来了挑战.
- 移植对宿主疾病 (GvHD) 预防对于成功的移植结果至关重要.
研究的目的:
- 审查使用移植后环胺 (PTCy) 的HLA不匹配和平分相同干细胞移植的供体选择策略.
- 为了比较基于 PTCy 的 GvHD 预防与传统方法关于捐赠者选择标准.
主要方法:
- 文献综述侧重于评估在PTCy条件下的血性恶性瘤干细胞移植中供体选择的研究.
- 分析影响移植,GvHD和生存的因素,包括HLA匹配,捐赠者特异性抗体 (DSA) 和捐赠者特征.
主要成果:
- 与传统的GvHD预防相比,PTCy显著降低了HLA不匹配的影响.
- 患者的捐赠者特异性抗体 (DSA) 是关键的;高水平和阳性C1q增加了移植失败的风险.
- 年轻的捐赠者年龄和HLA-B领导者匹配与改善的生存率有关. 首选的单双相同的捐赠者包括HLAII类不匹配的兄弟姐妹/后代,而非相关的捐赠者应该是HLAI类匹配的.
结论:
- 通过容忍HLA不匹配,PTCy扩大了捐赠者池,使得与HLA不匹配和HLA不匹配的非相关捐赠者成为可行的选择.
- 在PTCy下的捐赠者选择应优先考虑年轻的捐赠者,并考虑患者的DSA状态,HLA匹配标准不如常规预防那么严格.
- 需要进一步的研究来澄清在基于PTCy的移植中,供体性别,细胞巨血病毒血清状态和ABO不匹配的影响.
关键词:
DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA DSA哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈在 PTCy 中.供体年龄 供体年龄一个半完全相同的模样.没有关联的无关联的.更多相关视频
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
7.8K
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
7.0K
相关概念视频
01:24Tissue Transplantation
337
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
337
01:22Bone Marrow Sampling and Transplants
279
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
279
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
01:40Cell-mediated Immune Responses
66.8K
Overview
66.8K
01:19Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K